{"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"68"},{"groupId":"BG006","value":"38"},{"groupId":"BG007","value":"146"}],"units":"Participants"}],"groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"BG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"BG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"BG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"BG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"BG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"BG005","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"BG006","title":"Part 2: PF-06801591 300 mg (SC) for UC"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"}]}],"title":"18-44 Years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"28"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"66"}]}],"title":"45-64 Years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"76"}]}],"title":">=65 Years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"13"},{"groupId":"BG007","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"53"},{"groupId":"BG006","value":"25"},{"groupId":"BG007","value":"90"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"50"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"112"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"3"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"29"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Baseline population included all enrolled participants who received at least 1 dose of study treatment. One participant who enrolled in Part 2: PF-06801591 300 mg (SC) for UC arm was not treated."}